IRIS
FERRARA, ROBERTO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 3.202
EU - Europa 1.989
NA - Nord America 1.015
SA - Sud America 296
AF - Africa 33
AN - Antartide 1
OC - Oceania 1
Totale 6.537
Salva come PNG Salva come JPEG
Nazione #
SG - Singapore 2.037
RU - Federazione Russa 1.253
US - Stati Uniti d'America 928
CN - Cina 482
HK - Hong Kong 362
RO - Romania 265
BR - Brasile 248
VN - Vietnam 166
IT - Italia 146
FR - Francia 96
GB - Regno Unito 55
DE - Germania 41
MX - Messico 41
CA - Canada 36
IN - India 26
NL - Olanda 25
AR - Argentina 20
BD - Bangladesh 20
TR - Turchia 20
PL - Polonia 17
SE - Svezia 17
ZA - Sudafrica 17
ES - Italia 15
FI - Finlandia 13
LT - Lituania 12
UA - Ucraina 11
IQ - Iraq 10
ID - Indonesia 9
JP - Giappone 9
PK - Pakistan 8
SA - Arabia Saudita 8
AT - Austria 7
EC - Ecuador 7
CO - Colombia 6
AE - Emirati Arabi Uniti 5
IE - Irlanda 4
KZ - Kazakistan 4
MA - Marocco 4
MY - Malesia 4
UZ - Uzbekistan 4
VE - Venezuela 4
AZ - Azerbaigian 3
CZ - Repubblica Ceca 3
DZ - Algeria 3
ET - Etiopia 3
IL - Israele 3
JM - Giamaica 3
JO - Giordania 3
NI - Nicaragua 3
NP - Nepal 3
PH - Filippine 3
TH - Thailandia 3
UY - Uruguay 3
BH - Bahrain 2
BO - Bolivia 2
CH - Svizzera 2
OM - Oman 2
PE - Perù 2
PT - Portogallo 2
PY - Paraguay 2
TT - Trinidad e Tobago 2
TW - Taiwan 2
AQ - Antartide 1
BA - Bosnia-Erzegovina 1
BE - Belgio 1
BJ - Benin 1
CI - Costa d'Avorio 1
CL - Cile 1
CY - Cipro 1
DO - Repubblica Dominicana 1
EG - Egitto 1
HN - Honduras 1
HU - Ungheria 1
IR - Iran 1
KE - Kenya 1
LV - Lettonia 1
NG - Nigeria 1
NZ - Nuova Zelanda 1
PS - Palestinian Territory 1
RS - Serbia 1
SR - Suriname 1
SY - Repubblica araba siriana 1
TN - Tunisia 1
Totale 6.537
Salva come PNG Salva come JPEG
Città #
Hong Kong 359
Singapore 293
Moscow 268
San Jose 200
Ashburn 153
Beijing 148
Dallas 127
Hefei 96
Lauterbourg 80
Ho Chi Minh City 59
New York 52
Los Angeles 38
Milan 34
Hanoi 26
Mexico City 24
Santa Clara 24
São Paulo 24
Rome 21
Orem 19
Denver 18
Montreal 14
Warsaw 14
Munich 13
Manchester 12
Pasadena 12
Brooklyn 11
Da Nang 11
Shanghai 11
Stockholm 11
Johannesburg 10
Rio de Janeiro 10
Toronto 10
Ankara 9
Cesano Boscone 9
Haiphong 9
Poplar 9
Boardman 8
Boston 8
Chennai 8
Falkenstein 8
Helsinki 8
Houston 8
Phoenix 8
Amsterdam 7
Florence 7
Nuremberg 7
Tianjin 7
Assago 6
Brasília 6
Council Bluffs 6
Frankfurt am Main 6
Kyiv 6
Tokyo 6
Guangzhou 5
Istanbul 5
London 5
Naples 5
Porto Alegre 5
Querétaro 5
Riyadh 5
Rotherham 5
Seattle 5
Adams Center 4
Baghdad 4
Barnet 4
Calgary 4
Campinas 4
Can Tho 4
City of London 4
Dhaka 4
Goiânia 4
Miami 4
Milwaukee 4
Shenzhen 4
Tashkent 4
Aalsmeer 3
Atlanta 3
Baie-D'Urfé 3
Baku 3
Bauru 3
Blumenau 3
Bogotá 3
Buffalo 3
Chicago 3
Fortaleza 3
Guarulhos 3
Guayaquil 3
Ha Long 3
Hangzhou 3
Iesi 3
Long Xuyen 3
Managua 3
New Delhi 3
Quilmes 3
Quito 3
Ribeirão Preto 3
Sorocaba 3
Teresópolis 3
Thái Bình 3
Turku 3
Totale 2.530
Salva come PNG Salva come JPEG
Nome #
Autoantibody positivity predicts severity of rheumatic immune-related adverse events to immune-checkpoint inhibitors 373
Genomics and Immunomics in the Treatment of Urothelial Carcinoma 188
Integrating clinical and biological prognostic biomarkers in patients with advanced NSCLC treated with immunotherapy: the DEMo score system 187
Hyperprogressive Disease upon Immune Checkpoint Blockade: Focus on Non-small Cell Lung Cancer 186
Uncommon targets in non-small cell lung cancer: Everyone wants a slice of cake 184
Exploring machine learning tools in a retrospective case-study of patients with metastatic non-small cell lung cancer treated with first-line immunotherapy: A feasibility single-centre experience 182
OncoAlert Round Table Discussions: The Global COVID-19 Experience 180
Impact of Intercurrent Introduction of Steroids on Clinical Outcomes in Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients under Immune-Checkpoint Inhibitors (ICI) 178
Facing the First-line in Metastatic Non-small-cell Lung Cancer – Immunotherapy and Chemotherapy 164
High bone tumor burden to identify advanced non-small cell lung cancer patients with survival benefit upon bone targeted agents and immune checkpoint inhibitors 157
Current and developing therapies for the treatment of non-small cell lung cancer with ALK abnormalities: update and perspectives for clinical practice 113
Tocilizumab for the treatment of immune-related adverse events: a systematic literature review and a multicentre case series 112
Evaluation of Major Pathologic Response and Pathologic Complete Response as Surrogate End Points for Survival in Randomized Controlled Trials of Neoadjuvant Immune Checkpoint Blockade in Resectable in NSCLC 104
Systematic review and meta-analysis of immune checkpoint inhibitors as single agent or in combination with chemotherapy in early-stage non-small cell lung cancer: Impact of clinicopathological factors and indirect comparison between treatment strategies 95
Sex dimorphism and cancer immunotherapy: May pregnancy solve the puzzle? 88
Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: Results from the expanded access program 81
DiM: Prognostic Score for Second- or Further-line Immunotherapy in Advanced Non-Small-Cell Lung Cancer: An External Validation 79
Brief Report: Canadian Cancer Trials Group IND.227: A Phase 2 Randomized Study of Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma (NCT02784171) 78
Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer 78
Lung neuroendocrine tumours: deep sequencing of the four World Health Organization histotypes reveals chromatin-remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D 77
Hyperprogressive disease: recognizing a novel pattern to improve patient management 77
Prognostic value of histogram analysis in advanced non-small cell lung cancer: a radiomic study 76
Myeloid cell heterogeneity in lung cancer: implication for immunotherapy 76
Immune-Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer With Uncommon Histology 74
Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer 73
Afatinib in patients with metastatic or recurrent HER2-mutant lung cancers: a retrospective international multicentre study 72
Association of the prognostic model iSEND with PD-1/L1 monotherapy outcome in non-small-cell lung cancer 71
Beyond First-Line Immunotherapy: Potential Therapeutic Strategies Based on Different Pattern Progressions: Oligo and Systemic Progression 69
Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers-Letter 68
An overview of angiogenesis inhibitors in Phase II studies for non-small-cell lung cancer 68
CD8+PD-1+ to CD4+PD-1+ ratio (PERLS) is associated with prognosis of patients with advanced NSCLC treated with PD-(L)1 blockers 68
ALK gene copy number gains in non-small-cell lung cancer: prognostic impact and clinico-pathological correlations 67
Predictive biomarkers of response for immune checkpoint inhibitors in non-small-cell lung cancer 67
RET-MAP: An International Multicenter Study on Clinicobiologic Features and Treatment Response in Patients With Lung Cancer Harboring a RET Fusion 65
Adjuvant therapy for resected early-stage small-cell lung cancer: is now time to rethink about that? 64
A Case of William's Syndrome in a Ugandan Child: A Feasible Diagnosis Even in a Low-Resource Setting 62
Adenosine Pathway in NSCLC With Molecular Drivers: Can Oncogene Addiction Translate Into Immune Addiction? 62
Comparison of Fast-Progression, Hyperprogressive Disease, and Early Deaths in Advanced Non-Small-Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or Chemotherapy 62
Benefits and Harms of Lung Cancer Screening by Chest Computed Tomography: A Systematic Review and Meta-Analysis 60
Adjuvant epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for the treatment of people with resected stage I to III non‐small‐cell lung cancer and EGFR mutation 59
Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): what to add and what to leave out 58
Characterization of patients with metastatic non-small-cell lung cancer obtaining long-term benefit from immunotherapy 58
Immunotherapy 57
SMO mutations confer poor prognosis in malignant pleural mesothelioma 57
Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria 56
Atypical patterns of response and progression in the era of immunotherapy combinations 55
Clarification of Definitions of Hyperprogressive Disease During Immunotherapy for Non-Small Cell Lung Cancer 54
Acquired hemophagocytic syndrome in a patient with synovial sarcoma: a case report 53
Evaluation of Drug-Drug Interactions in EGFR-Mutated Non-Small-Cell Lung Cancer Patients during Treatment with Tyrosine-Kinase Inhibitors 53
EPSILoN: A Prognostic Score for Immunotherapy in Advanced Non-Small-Cell Lung Cancer: A Validation Cohort 52
Early Circulating Tumor DNA Dynamics and Efficacy of Lorlatinib in Patients With Treatment-Naive, Advanced, ALK-Positive NSCLC 51
Survival of patients with non-small cell lung cancer having leptomeningeal metastases treated with immune checkpoint inhibitors 51
Shifting From a "One Size Fits All" to a Tailored Approach for Immune-Related Adverse Events 51
Cancer care during the spread of coronavirus disease 2019 (COVID-19) in Italy: young oncologists' perspective 51
Outcome of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint Inhibitors 51
Efficacy and safety of immunotherapy in elderly patients with non-small cell lung cancer 50
Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer 49
Clinical and Translational Implications of RET Rearrangements in Non-Small Cell Lung Cancer 48
Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer 48
Immune checkpoint inhibitors versus second line chemotherapy for patients with lung cancer refractory to first line chemotherapy 47
Circulating T-cell Immunosenescence in Patients with Advanced Non-small Cell Lung Cancer Treated with Single-agent PD-1/PD-L1 Inhibitors or Platinum-based Chemotherapy 46
Immune checkpoint inhibitors and chemotherapy in first-line NSCLC: a meta-analysis 46
Integrating Circulating Biomarkers in the Immune Checkpoint Inhibitor Treatment in Lung Cancer 45
Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy 45
Human virome profiling identified CMV as the major viral driver of a high accumulation of senescent CD8+ T cells in patients with advanced NSCLC 44
Immunotherapy in advanced Non-Small Cell Lung Cancer patients with poor performance status: The role of clinical-pathological variables and inflammatory biomarkers 44
The Prognostic Role of TNM Staging Compared With Tumor Volume and Number of Pleural Sites in Malignant Pleural Mesothelioma 44
Wide and Cystic Brain Metastases Reveal RET-Rearranged Non-Small-Cell Lung Cancers 43
Tubulin inhibitors in non-small cell lung cancer: looking back and forward 43
Diagnosis and treatment of early and locally advanced non-small-cell lung cancer: The 2019 AIOM (Italian Association of Medical Oncology) clinical practice guidelines 42
Machine Learning Using Real-World and Translational Data to Improve Treatment Selection for NSCLC Patients Treated with Immunotherapy 42
The Anti–Programmed Cell Death Protein-1/ Programmed Death-Ligand 1 Me-Too Drugs Tsunami: Hard To Be Millennials Among Baby Boomers 42
Hyperprogression and Immune Checkpoint Inhibitors: Hype or Progress? 41
Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors 41
Do immune checkpoint inhibitors need new studies methodology? 40
Progress in the Management of Advanced Thoracic Malignancies in 2017 39
The development of PARP as a successful target for cancer therapy 39
The challenge of the Molecular Tumor Board empowerment in clinical oncology practice: A Position Paper on behalf of the AIOM- SIAPEC/IAP-SIBioC-SIC-SIF-SIGU-SIRM Italian Scientific Societies 39
Immune checkpoint inhibitors for non-small-cell lung cancer: does that represent a 'new frontier'? 39
Unexpected Huge Prevalence of Intracardiac Extension of Wilms Tumor—A Single Center Experience from a Ugandan Hospital 38
Hyperprogression-Immunotherapy-Related Phenomenon vs Intrinsic Natural History of Cancer-In Reply 38
Pseudoprogression in Non-Small Cell Lung Cancer upon Immunotherapy: Few Drops in the Ocean? 38
Circulating innate immune markers and outcomes in treatment-naïve advanced non-small cell lung cancer patients 38
The coming of ramucirumab in the landscape of anti-angiogenic drugs: potential clinical and translational perspectives 38
How to recognize and manage hyper-progression and pseudo-progression during immune checkpoint blockade in non-small cell lung cancer 38
Stereotatic radiotherapy in metastatic non-small cell lung cancer: Combining immunotherapy and radiotherapy with a focus on liver metastases 37
Modulation of PD-1/PD-L1 axis in myeloid-derived suppressor cells by anti-cancer treatments 37
Immunosenescence and immunecheckpoint inhibitors in non-small cell lung cancer patients: Does age really matter? 35
Is There an Interplay between Immune Checkpoint Inhibitors, Thromboprophylactic Treatments and Thromboembolic Events? Mechanisms and Impact in Non-Small Cell Lung Cancer Patients 35
Novel patterns of progression upon immunotherapy in other thoracic malignancies and uncommon populations 33
Clarification of Definitions of Hyperprogressive Disease During Immunotherapy-Reply 32
Treatment of advanced non-small-cell lung cancer: The 2019 AIOM (Italian Association of Medical Oncology) clinical practice guidelines 32
Is hyperprogressive disease a specific phenomenom of immunotherapy? 30
Robotic Surgery Is a Safe Treatment in Very Elderly Patients with Resectable Lung Cancer 25
Multidisciplinary management of N2 stage III non-small cell lung cancer: opportunities and challenges for radiation oncology 22
APOLLO 11 Project, Consortium in Advanced Lung Cancer Patients Treated With Innovative Therapies: Integration of Real-World Data and Translational Research 5
A viable human lung cancer tissue collection (LCTC) to accelerate translational research 5
STYLE (NCT03449173): A Phase 2 Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines 4
Blinded independent central review versus local investigator assessment of PFS in RCTs of immunotherapy in advanced cancers: A systematic review and meta-analysis 3
Improved Event-Free Survival After Complete or Major Pathologic Response in Patients With Resectable NSCLC Treated With Neoadjuvant Chemoimmunotherapy Regardless of Adjuvant Treatment: A Systematic Review and Individual Patient Data Meta-Analysis 2
Totale 6.663
Salva come PNG Salva come JPEG
Categoria #
all - tutte 18.097
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 18.097
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222 0 0 2 0 0 0 0 0 0 0 0 0
2022/202314 3 2 1 0 0 1 1 2 0 0 2 2
2023/202440 2 4 2 2 2 5 6 3 3 3 1 7
2024/20252.532 16 6 1 6 9 7 404 66 214 300 761 742
2025/20264.087 383 308 146 440 413 170 417 321 1.282 207 0 0
Totale 6.675